Evidence map›Paper›PMID 41631160›Full record

ArticleMolecular therapy. Oncology2026

A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity.

Sabine Heinze, Giovanna L Stadler, Yonghui Zhang, Christine E Engeland, Thomas F E Barth, Johannes P W Heidbuechel, Lüder H Meyer, Michael D Mühlebach, Klaus-Michael Debatin, Carmen Dorneburg and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sabine HeinzeDepartment of Pediatrics and Adolescent Medicine, University Medical Center Ulm, 89075 Ulm, Germany.
Giovanna L StadlerDepartment of Pediatrics and Adolescent Medicine, University Medical Center Ulm, 89075 Ulm, Germany.
Yonghui ZhangHenan Key Laboratory of Stem Cell Clinical Application and Key Technology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Henan 450003, China.
Christine E EngelandExperimental Hematology and Immunotherapy, Medical Department for Haematology, Cell Therapy, Hemostaseology and Infectiology and Medical Faculty, Leipzig University, 04103 Leipzig, Germany.
Thomas F E BarthInstitute of Pathology, University Medical Center Ulm, 89081 Ulm, Germany.
Johannes P W HeidbuechelClinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Lüder H MeyerDepartment of Pediatrics and Adolescent Medicine, University Medical Center Ulm, 89075 Ulm, Germany.
Michael D MühlebachDivision Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Klaus-Michael DebatinDepartment of Pediatrics and Adolescent Medicine, University Medical Center Ulm, 89075 Ulm, Germany.
Carmen DorneburgDepartment of Pediatrics and Adolescent Medicine, University Medical Center Ulm, 89075 Ulm, Germany.
Christian BeltingerDepartment of Pediatrics and Adolescent Medicine, University Medical Center Ulm, 89075 Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Children with high-risk B-cell precursor acute lymphoblastic leukemia (BCP-ALL) continue to face relapse and treatment resistance, emphasizing the urgent need for novel therapeutic strategies. In this study, we developed and characterized a recombinant oncolytic measles virus (MV-Blina) engineered to locally secrete a bispecific T cell engager (bsTE) targeting CD19 and CD3 (secBlina) to enhance antitumor immunity while minimizing systemic toxicity. MV-Blina demonstrated superior replication kinetics and cytotoxicity

Indexed as

acute lymphoblastic leukemiabispecific T cell engagerbsTEMT: Regular Issueoncolytic measles virustoxicityVirotherapy

Identifiers

PMID41631160
PMCPMC12860616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.